Приказ основних података о документу

dc.creatorUseini, Liridona
dc.creatorKomazec, Teodora
dc.creatorLaube, Markus
dc.creatorLönnecke, Peter
dc.creatorSchädlich, Jonas
dc.creatorMijatović, Sanja
dc.creatorMaksimović-Ivanić, Danijela
dc.creatorPietzsch, Jens
dc.creatorHey-Hawkins, Evamarie
dc.date.accessioned2023-06-12T08:51:22Z
dc.date.available2023-06-12T08:51:22Z
dc.date.issued2023
dc.identifier.issn2366-3987
dc.identifier.urihttp://radar.ibiss.bg.ac.rs/handle/123456789/5826
dc.description.abstractNonsteroidal anti-inflammatory drugs (NSAIDs) are the most widely used therapeutics against pain, fever, and inflammation; additionally, antitumor properties are reported. NSAIDs reduce the synthesis of prostaglandins by inhibiting the cyclooxygenase (COX) isoforms COX-1 and COX-2. As nonselective inhibition is associated with off-target effects, strategies to achieve selectivity for the clinically preferred isoform COX-2 are of high interest. The modification of NSAIDs using carborane clusters as phenyl mimetics is reported to alter the selectivity profile through size exclusion. Inspired by these findings, isonimesulide and its carborane derivatives are prepared. The biological screening shows that the carborane containing compounds exhibit a stronger antitumor potential compared to nimesulide and isonimesulide. Furthermore, the replacement of the phenyl ring of isonimesulide with a carborane moiety resulted in a shift of the COX activity from nonactive to COX-active compounds.sr
dc.language.isoensr
dc.publisherHoboken: Wileysr
dc.relationThe Deutscher Akademischer Austauschdienst (DAAD, Research Grants–Doctoral Programs in Germany 2018/2019, Funding Program No. 57381412)sr
dc.relationThe Graduate School Leipzig School of Natural Sciences – Building with Molecules and Nanoobjects (BuildMoNa)sr
dc.relationThe German Research Foundation (Deutsche Forschungsgemeinschaft)sr
dc.relationinfo:eu-repo/grantAgreement/MESTD/inst-2020/200007/RS//sr
dc.rightsopenAccesssr
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceAdvanced Therapeuticssr
dc.subjectcancersr
dc.subjectcarboranesr
dc.subjectcyclooxygenasesr
dc.subjectdrug designsr
dc.subjectinflammationssr
dc.subjectnimesulidesr
dc.subjectnonsteroidal anti-inflammatory drugssr
dc.titleIsonimesulide and Its Carborane Analogues as Isoform-Selective COX Inhibitors and Antitumor Agentssr
dc.typearticlesr
dc.rights.licenseBY-NC-NDsr
dc.rights.holder© 2023 The Authors. Advanced Therapeutics published by Wiley-VCH GmbHsr
dc.identifier.doi10.1002/adtp.202300117
dc.identifier.scopus2-s2.0-85159871400
dc.identifier.wos000993381800001
dc.citation.apaUseini, L., Komazec, T., Laube, M., Lönnecke, P., Schädlich, J., Mijatović, S., et al. (2023). Isonimesulide and Its Carborane Analogues as Isoform-Selective COX Inhibitors and Antitumor Agents. Advanced Therapeutics, 2300117.
dc.citation.vancouverUseini L, Komazec T, Laube M, Lönnecke P, Schädlich J, Mijatović S, Maksimović-Ivanić D, Pietzsch J, Hey-Hawkins E. Isonimesulide and Its Carborane Analogues as Isoform-Selective COX Inhibitors and Antitumor Agents. Adv Ther. 2023;2300117.
dc.citation.spage2300117
dc.type.versionpublishedVersionsr
dc.identifier.fulltexthttps://radar.ibiss.bg.ac.rs/bitstream/id/13615/bitstream_13615.pdf
dc.citation.rankM21~


Документи

Thumbnail

Овај документ се појављује у следећим колекцијама

Приказ основних података о документу